Key Takeaways
Agilon Health Inc. (NYSE: AGL) shares more than doubled Thursday after the healthcare company posted first-quarter results that significantly beat expectations and raised its full-year financial outlook, signaling a potential turnaround after a difficult 2025.
"The strong first-quarter showing strengthens his conviction that Agilon offers an 'exceedingly positive' skew between risk and reward," Jefferies analyst Jack Slevin said, who upgraded the stock to Buy from Hold. Wall Street responded with a flurry of upgrades, reassured by the company's improved cost controls and strategic adjustments.
For the first quarter of 2026, Agilon reported a 7% decline in revenue to $1.42 billion, which was still ahead of the $1.38 billion analyst consensus. The key driver for investors was profitability. Adjusted earnings before interest, taxes, depreciation, and amortization (EBITDA) reached $54 million, a 162% increase from the prior year and well above the $37 million consensus estimate.
The most significant development was the upward revision of its full-year guidance. Agilon now targets a 2026 adjusted EBITDA of $25 million at the midpoint, a stark contrast to the $12 million loss analysts had anticipated. The company also lifted its revenue outlook to a range of $5.68 billion to $5.81 billion.
This performance marks a sharp reversal from 2025, when the stock plummeted 64% amid massive medical margin losses and a guidance suspension that damaged investor confidence. The company's strategic decision, announced in February, to exit unprofitable contracts representing 50,000 Medicare Advantage members appears to be boosting profitability, sacrificing scale for better unit economics.
Analyst sentiment shifted decisively following the report. Jefferies raised its price target to $48 from $27.50. Deutsche Bank analyst George Hill upgraded the stock to Buy, increasing his target to $49, pointing to "an improving macro environment and a compelling valuation."
The guidance raise suggests management is confident that its physician-centric Total Care Model is generating operating leverage. The positive results indicate Agilon is improving its ability to manage costs for its Medicare patients, a core challenge for the health services industry. Investors will now watch to see if the company can maintain this profitability momentum in the coming quarters.
This article is for informational purposes only and does not constitute investment advice.
